GT Biopharma Analyst Ratings
GT Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/05/2023 | 96.08% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 09/13/2022 | 390.2% | HC Wainwright & Co. | $25 → $5 | Maintains | Buy |
| 05/24/2021 | 2350.98% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/13/2021 | 1958.82% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 03/17/2021 | 2350.98% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 01/05/2023 | 96.08% | EF Hutton | →$2 | 開始承保 | →保留 |
| 09/13/2022 | 390.2% | HC Wainwright公司 | $25→$5 | 維護 | 買 |
| 2021/05/24 | 2350.98% | HC Wainwright公司 | →$25 | 開始承保 | →購買 |
| 04/13/2021 | 1958.82% | B.萊利證券 | →$21 | 開始承保 | →購買 |
| 03/17/2021 | 2350.98% | 羅斯資本 | →$25 | 開始承保 | →購買 |
What is the target price for GT Biopharma (GTBP)?
GT Biophma(GTBP)的目標價格是多少？
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by EF Hutton on January 5, 2023. The analyst firm set a price target for $2.00 expecting GTBP to rise to within 12 months (a possible 96.08% upside). 2 analyst firms have reported ratings in the last year.
GT Biophma(納斯達克：GTBP)的最新目標價是由EF Hutton於2023年1月5日報道的。這家分析公司將目標價定為2.00美元，預計英鎊將在12個月內上漲(可能上漲96.08%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for GT Biopharma (GTBP)?
GT Biophma(GTBP)的最新分析師評級是什麼？
The latest analyst rating for GT Biopharma (NASDAQ: GTBP) was provided by EF Hutton, and GT Biopharma initiated their hold rating.
GT Biophma(納斯達克代碼：GTBP)的最新分析師評級由EF Hutton提供，GT Biophma啟動了他們的持有評級。
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
GT Biophma(GTBP)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on January 5, 2023 so you should expect the next rating to be made available sometime around January 5, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與GT Biophma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。GT Biophma的最後一次評級是在2023年1月5日提交的，所以你應該預計下一次評級將在2024年1月5日左右的某個時候提供。
Is the Analyst Rating GT Biopharma (GTBP) correct?
分析師對GT Biophma(GTBP)的評級正確嗎？
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a initiated with a price target of $0.00 to $2.00. The current price GT Biopharma (GTBP) is trading at is $1.02, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的GT Biophma(GTBP)評級是以0.00美元至2.00美元的目標價啟動的。GT Biophma(GTBP)目前的交易價格為1.02美元，在分析師的預測範圍內。